Based on the examination, on February 5, 2021, the BPOM released the EUA for CoronaVac for people aged 60 years of ages and above.
Jakarta – Indonesia’s COVID-19 Dealing with Task Force verified that CoronaVac is safe to use for senior citizens, as the National Food and Drug Control Firm (BPOM) had actually released an Emergency situation Usage Permission (EUA) for the vaccine.
” Based upon the evaluation, on February 5, 2021, the BPOM had actually issued the EUA for CoronaVac for people aged 60 years and above, with 2 doses of vaccine injections given at an interval of 28 days,” Prof. Wiku Adisasmito, a spokesperson of the job force, noted in a statement here on Wednesday.
Top priority has been accorded to the elderly population to get the COVID-19 vaccine shot, as the death rate connected with the coronavirus illness has actually continued to increase, and the group is at high danger of infection.
The vaccine will initially be administered to medical employees in the senior group.
Adisasmito mentioned that the EUA was provided after conducting comprehensive evaluation and was based on the outcome of clinical trials in Brazil and China.
The approval was provided through conversations performed by the BPOM with associated celebrations, such as the National Commission for Drug Examination, Indonesian Technical Advisory Group on Immunization (ITAGI), allergic reaction and immunology professionals, and geriatric experts on the outcomes of the CoronaVac vaccine clinical trials in China and Brazil including groups aged 60 years and above.
The BPOM had actually earlier kept an eye on and acquired the medical trial information for the very first and 2nd stages of the CoronaVac vaccine in China and the third stage in Brazil. The approval was given after analyzing the scientific trial information in both countries.
The move was aimed at gathering data on the security and efficacy of the vaccine for the elderly.
” At the end of January 2021, the 2nd stage of the medical trial in China and the 3rd phase of the trial in Brazil, involving groups aged 60 years and above, had reached adequate topics, and the details were sent to the BPOM for evaluation,” he exposed.
For the next phase of the vaccination program covering public service officers, Indonesia will produce its own COVID-19 vaccine.
The state-owned vaccine manufacturer PT Bio Farma will produce the vaccine for the program.
” Thus, Indonesia can accomplish self-sufficiency in vaccine supply and be all set to run its vaccination program for civil service officers after the conclusion of vaccination for medical workers,” he affirmed.
Earlier, BPOM Head Cent K. Lukito noted that the agency had actually issued an approval for the emergency usage of the CoronaVac vaccine produced by China’s Sinovac Biotech for the elderly aged 60 years and above.
Regardless of the approval for emergency use, Lukito called to exercise prudence and caution in immunizing the elderly population given that this group is at high risk and tends to have comorbidities.
” The 3rd phase of clinical trials that took place in Brazil included 600 senior topics. It shows that giving this vaccine to the age group of 60 years and above is safe, without any serious side-effects being reported,” she said.
Lukito also pointed to mild side-effects reported throughout the medical trial, such as discomfort, nausea, fever, swelling, inflammation of the skin, and headaches.
Associated news: Arrival of CoronaVac in Indonesia raises hopes
Associated news: East Java’s 2.5 million senior citizens to get second COVID-19 vaccines
EDITED BY INE
